ASND Share Price Performance
US$174.48
49.49 (39.60%)
41.4% undervalued intrinsic discount
US$297.65
Fair Value
Price US$174.48
AnalystHighTarget US$297.65
AnalystConsensusTarget US$232.86
AnalystLowTarget US$193.36
Fair ValueUS$297.65
Share PriceUS$174.48
41.4% undervalued intrinsic discount
ASND Community Narratives
AN
Fair Value US$297.65 41.4% undervalued intrinsic discount
Growing Aging Trends Will Fuel TransCon Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$232.86 25.1% undervalued intrinsic discount
Upcoming SKYTROFA And YORVIPATH Launches Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$193.36 9.8% undervalued intrinsic discount
Persistent Pricing Pressures Will Compress Margins While Orphan Demand Expands
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ASND Community Fair Values
- US$232.86FV25.1% undervalued intrinsic discount73.49%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative4users have followed this narrative5 days ago author updated this narrative
- US$297.65FV41.4% undervalued intrinsic discount98.24%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative12 days ago author updated this narrative
- US$193.36FV9.8% undervalued intrinsic discount63.83%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative12 days ago author updated this narrative
Recent ASND News & Updates
No updates
Ascendis Pharma A/S Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- -5.64
- Gross Margin
- 85.30%
- Net Profit Margin
- -92.67%
- Debt/Equity Ratio
- -396.7%
Ascendis Pharma A/S Competitors
About ASND
- Founded
- 2006
- Employees
- 1017
- CEO
- WebsiteView website
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Danish Market Performance
- 7 Days: -16.6%
- 3 Months: -12.6%
- 1 Year: -39.1%
- Year to Date: -28.6%
Over the last 7 days, the market has dropped 17%, driven by pullbacks in every sector, especially the Healthcare sector. In the last 12 months the market is down 39%. Looking forward, earnings are forecast to grow by 6.7% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading